Denali Therapeutics Announces Upcoming Presentations On EIF2B Activator DNL343 And RIPK1 Inhibitor SAR443820/DNL788 At 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting Oct. 6